Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR101 in peanut-allergic children aged 1 to < 4 years
NCT03736447Phase 3Completed
- Start
- Dec 2018
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing AR101 with Placebo (2 arms). Primary endpoint: Percentage of Subjects Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) at 12 months. Started Dec 2018; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03736447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736447.